Maltose dependent degrons, maltose-responsive promoters, stabilization constructs, and their use in production of non-catabolic compounds
The present disclosure relates to the use of a maltose dependent degron to control stability of a protein of interest fused thereto at the post-translational level. The present disclosure also relates to the use of a maltose dependent degron in combination with a maltose-responsive promoter to control gene expression at the transcriptional level and to control protein stability at the post-translational level. The present disclosure also relates to the use of a stabilization construct that couples expression of a cell-growth-affecting protein with the production of non-catabolic compounds. The present disclosure further relates to the use of a synthetic maltose-responsive promoter. The present disclosure further provides compositions and methods for using a maltose dependent degron, a maltose-responsive promoter, and a stabilization construct, either alone or in various combinations, for the production of non-catabolic compounds in genetically modified host cells.
1. A method of controlling expression and stability of a protein of interest in genetically modified host cells, the method comprising:
a. culturing a population of a genetically modified host cell in a culture medium comprising a carbon source comprising a maltose based inducer, wherein the genetically modified host cell comprises a heterologous nucleic acid encoding a fusion protein comprising a protein of interest fused in frame to a maltose dependent degron; and
b. culturing the population or a subpopulation thereof in a culture medium comprising a carbon source, wherein the maltose based inducer is absent or in sufficiently low amounts compared to the culture medium in step (a),
wherein the maltose dependent degron in the fusion protein comprises an amino acid sequence of SEQ ID NO: 2 or SEQ ID NO: 28, and comprises one or more variant amino acid residues selected from the group consisting of K7R, I10T, W11G, L21S, V24A, F28Y, D42V, K43E, A64T, F68S, D83G, D88N, P92T, W95R, V98I, N101I, A110T, I117V, P134S, A135T, L136M, M149I, Y168C, Y168N, Y177H, N186S, A187P, L193S, D198V, D210E, A216V, A217D, G229C, I236N, D237N, N242D, L263M, L291V, A304S, T321N, M322L, A339T, A351T, T357S, T367S, S370P, and N374S, wherein positions of the one or more variant amino acid residues correspond to amino acid positions of SEQ ID NO: 2 or SEQ ID NO: 28.
2. The method of claim 1 , wherein the heterologous nucleic acid is operably linked to a maltose-responsive promoter.
3. The method of claim 2 , wherein the maltose-responsive promoter comprises a sequence selected from the group consisting of pMAL1 (SEQ ID NO: 29), pMAL2 (SEQ ID NO: 30), pMAL11 (SEQ ID NO: 31), pMAL12 (SEQ ID NO: 32), pMAL31 (SEQ ID NO: 33), pMAL32 (SEQ ID NO: 34), pMAL32_v1 (SEQ ID NO: 78), pGMAL_v5 (SEQ ID NO: 35), pGMAL_v6 (SEQ ID NO: 36), pGMAL_v7 (SEQ ID NO: 37), pGMAL_v9 (SEQ ID NO: 38), pGMAL_v10 (SEQ ID NO: 39), pGMAL_v11 (SEQ ID NO: 40), pGMAL_v12 (SEQ ID NO: 41), pGMAL_v13 (SEQ ID NO: 42), pGMAL_v14 (SEQ ID NO: 43), pGMAL_v15 (SEQ ID NO: 44), pGMAL_v16 (SEQ ID NO: 45), pGMAL_v17 (SEQ ID NO: 46), pGMAL_v18 (SEQ ID NO: 47), pG2MAL_v1 (SEQ ID NO: 48), pG2MAL_v2 (SEQ ID NO: 49), pG2MAL_v3 (SEQ ID NO: 50), pG2MAL_v5 (SEQ ID NO: 51), pG2MAL_v6 (SEQ ID NO: 52), pG2MAL_v7 (SEQ ID NO: 53), pG2MAL_v8 (SEQ ID NO: 54), pG2MAL_v9 (SEQ ID NO: 55), pG2MAL_v10 (SEQ ID NO: 56), pG7MAL_v2 (SEQ ID NO: 57), pG7MAL_v4 (SEQ ID NO: 58), pG7MAL_v6 (SEQ ID NO: 59), pG7MAL_v8 (SEQ ID NO: 60), pG7MAL_v9 (SEQ ID NO: 61), pG172_MAL_v13 (SEQ ID NO: 62), pG271_MAL_v12 (SEQ ID NO: 63), pG721_MAL_v11 (SEQ ID NO: 64), and pG712_MAL_v14 (SEQ ID NO: 65).
4. The method of claim 1 , wherein the heterologous nucleic acid encoding the fusion protein is integrated into a genome of the genetically modified host cell.
5. The method of claim 4 , wherein the heterologous nucleic acid integrated into the genome of the genetically modified host cell functionally disrupts an endogenous nucleic acid encoding the protein of interest.
6. The method of claim 1 , wherein the genetically modified host cell further comprises a biomolecule that interacts with the fusion protein in the host cell to modulate the levels of one or more target molecules.
7. The method of claim 6 , wherein the genetically modified host cell further comprises one or more heterologous nucleic acids encoding the one or more target molecules.
8. The method of claim 6 , wherein the biomolecule is Gal4p, and each of the one or more heterologous nucleic acids encoding the one or more target molecules is operably linked to a Gal4p-responsive promoter.
9. The method of claim 8 , wherein the Gal4p-responsive promoter is selected from the group consisting of pGAL1, pGAL2, pGAL7, pGAL10, pGCY1, pGAL80 and synthetic pGAL promoters.
10. The method of claim 6 , wherein the one or more target molecules are enzymes of a biosynthetic pathway, wherein the enzymes are negatively regulated by the activity of the fusion protein, and wherein the fusion protein is stable in the presence of the maltose based inducer.
11. The method of claim 10 , wherein the one or more target molecules further include non-catabolic compounds produced by the enzymes in the biosynthetic pathway.
12. The method of claim 11 , wherein the genetically modified host cell is capable of producing an isoprenoid compound and comprises at least one heterologous nucleic acid encoding an isoprenoid pathway enzyme.
13. The method of claim 12 , wherein at least one heterologous nucleic acid encoding an isoprenoid pathway enzyme is selected from the group consisting of:
a. an enzyme that condenses two molecules of acetyl-coenzyme A to form acetoacetyl-CoA;
b. an enzyme that condenses acetoacetyl-CoA with another molecule of acetyl-CoA to form 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA);
c. an enzyme that converts HMG-CoA into mevalonate;
d. an enzyme that converts mevalonate into mevalonate 5-phosphate;
e. an enzyme that converts mevalonate 5-phosphate into mevalonate 5-pyrophosphate;
f. an enzyme that converts mevalonate 5-pyrophosphate into IPP;
g. an enzyme that converts IPP into DMAPP;
h. a polyprenyl synthase that can condense IPP and/or DMAPP molecules to form polyprenyl compounds containing more than five carbons;
i. an enzyme that condenses IPP with DMAPP to form GPP;
j. an enzyme that condenses two molecules of IPP with one molecule of DMAPP;
k. an enzyme that condenses IPP with GPP to form FPP;
l. an enzyme that condenses IPP and DMAPP to form GGPP; and
m. an enzyme that condenses IPP and FPP to form GGPP.
14. The method of claim 13 , wherein the host cells further comprise a heterologous nucleic acid encoding an enzyme that modifies a polyprenyl, selected from the group consisting of a geraniol synthase, a linalool synthase, a limonene synthase, a myrcene synthase, an ocimene synthase, an α-pinene synthase, β-pinene synthase, a sabinene synthase, a γ-terpinene synthase, a terpinolene synthase, an amorphadiene synthase, an α-farnesene synthase, a β-farnesene synthase, a farnesol synthase, a nerolidol synthase, a patchouliol synthase, a nootkatone synthase, an abietadiene synthase.
15. The method of claim 13 , wherein the host cells comprise a plurality of heterologous nucleic acids encoding all the enzymes of a mevalonate pathway.
16. The method of claim 1 , wherein the protein of interest is a transcriptional regulator.
17. The method of claim 16 , wherein the protein of interest is Gal80p.
18. The method of claim 1 , wherein the host cell is selected from the group consisting of a fungal cell, a bacterial cell, a plant cell, and an animal cell.
19. The method of claim 18 , wherein the host cell is a yeast cell.